Stock APS APTOSE BIOSCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Aptose Biosciences Inc.

Equities

APS

CA03835T3091

Market Closed - Toronto S.E.
Other stock markets
 03:53:45 2024-04-23 pm EDT 		5-day change 1st Jan Change
1.65 CAD -2.94% Intraday chart for Aptose Biosciences Inc. -5.71% -50.75%
Mar. 26 Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 26 Transcript : Aptose Biosciences Inc., Q4 2023 Earnings Call, Mar 26, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : Aptose Biosciences Inc., Q4 2023 Earnings Call, Mar 26, 2024
Aptose Biosciences Up 3% After Hours as its 2023 Loss Widens on Higher R&D Spending
MT
Aptose Biosciences Brief: Says Luxeptinib G3 Formulation Achieved "Desired Levels and Positions for Future Trials"
MT
Aptose Biosciences Brief: Says Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML; Adds Tuspetinib "Continues Broad Activity Across Mutations with Excellent Safety Profile"
MT
Aptose Biosciences Brief: Q4 Basic and diluted loss per Common Share US$7.58
MT
Aptose Reports Results for the Fourth Quarter and Full Year 2023
AQ
Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Markets Steady -2-
DJ
North American Morning Briefing : Stock Futures -2-
DJ
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
AQ
Top Premarket Gainers
MT
Aptose Biosciences Down 3% After Hours as it Raises US$13.7 Million in a Bought-Deal Offering, Private Placement
MT
Aptose Biosciences Raises US$13.7 Million in a Bought-Deal Offering of Share Units and Concurrent Private Placement
MT
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
AQ
Aptose Biosciences Brief: Announcing Closing of US$9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
MT
Aptose Biosciences Inc. announced that it has received $4 million in funding from Hanmi Pharm. Co., Ltd.
CI
Wall Street Set to Open Marginally Lower Friday; December Inflation Data Lower Than Forecast
MT
Aptose Biosciences Priced US$8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharma
MT
US Futures Nudge Lower in Friday's Premarket Ahead of Fed Inflation Data
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APS Stock
  4. News Aptose Biosciences Inc.